Facebook
X

Phone: (843) 449-1010 | 823 82nd Parkway, Suite B, Myrtle Beach, SC 29572

Home
About Us
Staff
Current Trials
Patient Info
Testimonials
In The News
- In The News
Contact
Search
Menu Menu

Blog - Latest News

You are here: Home1 / ZERO Prostate Cancer Tee-Off2 / zero-20

zero-20

August 13, 2024/0 Comments/by CURC

Share this entry

Share on Facebook
Share on X
Share on X
Share on WhatsApp
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

/wp-content/uploads/logo-1.png 0 0 CURC /wp-content/uploads/logo-1.png CURC2024-08-13 15:32:512024-08-13 15:32:51zero-20

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Name *

Email *

Website

Comment *

Δ

Current Happenings

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?
Editorial Comment: Integrating Broad Panel Somatic and Germline Testing in Prostate Cancer Care
Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology
Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer
The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer

Archives

Archives

Contact

Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572

Phone: (843) 839-1679
Fax: (843) 286-0119

Email:
info@curcmb.com

Recent Happenings

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?

Our Affiliates

©2025 Carolina Urologic Research Center, LLC | All Rights Reserved | Site Design by Studio303, Inc.

Facebook
X